Brought to you by 
Novartis makes $43mm equity investment in GeneProt
23 Jul 2001
Executive Summary
GeneProt (formerly Geneva Proteomics) signed an agreement with Novartis to determine the protein profile of three human diseased tissues or body fluids. Novartis will buy $43mm in GeneProt equity and become its preferred pharmaceutical partner.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis makes $43mm equity investment in GeneProt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice